Form 4: Zevra Therapeutics Executive Rahsaan Thompson Reports Stock Option and Restricted Stock Unit Grants
SEC Form 4 Filing
Rahsaan Thompson, Chief Legal & Compliance Secretary at Zevra Therapeutics, reports the acquisition of stock options and restricted stock units.
Summary
- Rahsaan Thompson, Chief Legal & Compliance Secretary of Zevra Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- The report indicates the grant of a stock option to purchase 68,000 shares of common stock at an exercise price of $8.02, vesting in four equal annual installments starting January 30, 2026, and expiring on January 29, 2035.
- Thompson also received 34,000 restricted stock units (RSUs), each representing a contingent right to receive one share of Zevra Therapeutics common stock.
- One third of the RSUs will vest on January 30, 2026, with the remaining two thirds vesting in equal annual installments thereafter, contingent upon continued service.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating a stable and incentivized management structure. The sentiment is neutral to positive as it suggests alignment of interests between management and shareholders.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- The vesting schedules incentivize continued service and commitment to the company's long-term success.
Future Outlook
The vesting of the stock options and RSUs is contingent upon the Reporting Person's continued service with the company.
Industry Context
Granting stock options and RSUs to executives is a common practice in the pharmaceutical industry to incentivize performance and align management's interests with those of shareholders. These grants are typically part of a broader compensation package designed to attract and retain talent.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and RSUs to incentivize their executives.
- The vesting schedules and terms of these grants are generally comparable to industry norms, with vesting typically tied to continued service and performance milestones.
Stakeholder Impact
- Shareholders may view the grants positively as they align executive compensation with company performance.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/30/2025 | Date of earliest transaction (grant date of stock option and RSUs) |
| 01/30/2026 | First vesting date for both the stock option and one-third of the RSUs |
| 01/29/2035 | Expiration date of the stock option |
| 02/03/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.